Immune system study in transplant patients with blood clotting issues
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial studies patients who have had a stem cell or solid organ transplant and may have a condition called TMA (small blood clots in vessels) or a viral infection. It aims to understand how certain immune system parts (complement and interferon) affect these conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and willing to sign a consent form.
- You have had a stem cell or solid organ transplant, or you have a type of TMA caused by medication.
- If you have TMA, you must have a diagnosis confirmed by biopsy or by having at least 4 out of 6 specific blood and symptom changes (like anemia, low platelets, high LDH, schistocytes on blood smear, new or worsening high blood pressure, or protein in urine).
- If you don't have TMA, you may fit if you have had a transplant and either have a symptomatic viral infection (like a cold or flu) or no symptomatic infection.
- You cannot have a family or personal history of a rare form of TMA (aHUS), certain cancer (except the blood cancer you were treated for), or have taken certain immune drugs (complement inhibitors or interferon blockers) before.
- If female, you cannot be pregnant, breastfeeding, or planning pregnancy in the next year without using very reliable birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks for proteins in the blood that could help detect transplant-related blood vessel damage (called TMA) earlier, so doctors can treat it faster. It involves patients who have had a stem cell transplant from a donor.
This study looks at signs of a clotting problem in tiny blood vessels (called TMA) that can affect kidney function. The goal is to better understand the role of the body’s complement system and how it relates to different causes of this illness.
This trial tests a new drug, TGD001, for a condition called thrombotic microangiopathy (TMA), where small blood clots form in blood vessels and damage organs. The drug aims to break up clots and improve blood flow.
This trial builds a database to study patterns in blood tests and blood smear findings that can suggest small blood clots in the body. Joining may help researchers learn how to recognize and track these changes over time.
This study looks at people who have a blood clotting problem called TMA after a stem cell transplant from a donor. It gathers information from routine checkups to learn more about this condition.
This study looks at how often a serious blood clotting problem (TA-TMA) happens after stem cell transplants. It follows two groups: people at high risk for TA-TMA and those with severe GVHD, and may test a drug called eculizumab for those who get TA-TMA.
Hear when a new Thrombotic Microangiopathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.